当前位置：首页 SCI期刊 SCIE期刊医学中科院3区 JCRQ3 期刊介绍(非官网)

Diabetes TherapySCIE

国际简称：DIABETES THER 参考译名：糖尿病治疗

中科院分区
3区
CiteScore分区
Q1
JCR分区
Q3

基本信息：: ISSN：1869-6953; E-ISSN：1869-6961; 是否OA：开放; 是否预警：否; TOP期刊：否

出版信息：: 出版地区：ENGLAND; 出版商：Springer Healthcare; 出版语言：English; 出版周期：12 issues per year; 出版年份：2010; 研究方向：Medicine-Endocrinology, Diabetes and Metabolism

评价信息：: 影响因子：2.8; H-index：25; CiteScore指数：6.9; SJR指数：0.938; SNIP指数：0.999

发文数据：: Gold OA文章占比：99.79%; 研究类文章占比：82.64%; 年发文量：144; 自引率：0.0789...; 开源占比：0.9965; 出版撤稿占比：0; 出版国人文章占比：0.11; OA被引用占比：1

投稿咨询加急见刊

英文简介期刊介绍 CiteScore数据中科院SCI分区 JCR分区发文数据常见问题

英文简介Diabetes Therapy期刊介绍

Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.

The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.

期刊简介Diabetes Therapy期刊介绍

《Diabetes Therapy》自2010出版以来，是一本医学优秀杂志。致力于发表原创科学研究结果，并为医学各个领域的原创研究提供一个展示平台，以促进医学领域的的进步。该刊鼓励先进的、清晰的阐述，从广泛的视角提供当前感兴趣的研究主题的新见解，或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道医学领域的最新进展和新发现新突破等。该刊近一年未被列入预警期刊名单，目前已被权威数据库SCIE收录，得到了广泛的认可。

该期刊投稿重要关注点：

预计审稿时间： 6 Weeks
医学
ENDOCRINOLOGY & METABOLISM
SCIE
中科院3区
非预警

Cite Score数据（2024年最新版）Diabetes Therapy Cite Score数据

CiteScore：6.9
SJR：0.938
SNIP：0.999

学科类别	分区	排名	百分位
大类：Medicine 小类：Internal Medicine	Q1	35 / 167	79%
大类：Medicine 小类：Endocrinology, Diabetes and Metabolism	Q2	68 / 244	72%

CiteScore 是由Elsevier(爱思唯尔)推出的另一种评价期刊影响力的文献计量指标。反映出一家期刊近期发表论文的年篇均引用次数。CiteScore以Scopus数据库中收集的引文为基础，针对的是前四年发表的论文的引文。CiteScore的意义在于，它可以为学术界提供一种新的、更全面、更客观地评价期刊影响力的方法，而不仅仅是通过影响因子(IF)这一单一指标来评价。

历年Cite Score趋势图

中科院SCI分区Diabetes Therapy 中科院分区

中科院 2023年12月升级版 综述期刊：否 Top期刊：否

大类学科	分区	小类学科	分区
医学	3区	ENDOCRINOLOGY & METABOLISM 内分泌学与代谢	4区

中科院分区表 是以客观数据为基础，运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据，得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次，类似于“优、良、及格”等。最开始，这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区Diabetes Therapy JCR分区

2023-2024 年最新版

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：ENDOCRINOLOGY & METABOLISM	SCIE	Q3	97 / 186	48.1%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：ENDOCRINOLOGY & METABOLISM	SCIE	Q3	103 / 186	44.89%

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异，此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此，JCR将期刊按照学科门类和影响因子分为不同的分区，这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

发文数据

2023-2024 年国家/地区发文量统计

国家/地区数量
USA155
CHINA MAINLAND137
England99
Japan94
India49
GERMANY (FED REP GER)43
Denmark41
Italy41
Wales29
Sweden28

本刊中国学者近年发表论文

1、Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China
Author: Liu, Lei; Ruan, Zhen; Ung, Carolina Oi Lam; Zhang, Yawen; Shen, Yang; Han, Sheng; Jia, Ruxu; Qiao, Jingtao; Hu, Hao; Guo, Lixin

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 1, pp. 93-107. DOI: 10.1007/s13300-022-01336-7
2、Application of the PDCA Cycle for Managing Hyperglycemia in Critically Ill Patients
Author: Chen, Jie; Cai, Wenchao; Lin, Feng; Chen, Xiaochu; Chen, Rui; Ruan, Zhanwei

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 2, pp. 293-301. DOI: 10.1007/s13300-022-01334-9
3、Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Hypertensive and/or Diabetic People Aged over 60 Years: A Prospective Open-Label Study
Author: Huang, Rongdong; Liu, Xiaoqin; Xie, Fangqin; Li, Junrong; Tang, Zhangbin; Wu, Yuying; Zhou, Peicong; Zhang, Dongjuan

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 1, pp. 139-151. DOI: 10.1007/s13300-022-01343-8
4、Risk Factors for Glycemic Control in Hospitalized Patients with Type 2 Diabetes Receiving Continuous Subcutaneous Insulin Infusion Therapy
Author: Wang, Shun-hua; Shao, Wei; Jiang, Qiu-hui; Zheng, Xuan-ling; Shen, Qing-bao; Lin, Xiao-yan; Zhang, Qiao-qing; Zhang, Lu-lu; Shi, Xiu-lin; Wang, Wen-gui; Li, Xue-jun

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 1, pp. 167-178. DOI: 10.1007/s13300-022-01342-9
5、Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis
Author: Wang, Hong; Xie, Xiaoya; Zu, Quannan; Lu, Ming; Chen, Rongfa; Yang, Zhiren; Gao, Yongqiang; Tang, Zhangui

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 1, pp. 47-61. DOI: 10.1007/s13300-022-01350-9
6、Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis
Author: Jiang, Zhiming; Liu, Le; Bundhun, Pravesh Kumar

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 2, pp. 387-399. DOI: 10.1007/s13300-022-01354-5
7、Independent and Joint Associations of Age, Pre-pregnancy BMI, and Gestational Weight Gain with Adverse Pregnancy Outcomes in Gestational Diabetes Mellitus
Author: Lee, Chee S.; Zhu, Shuqi; Wu, Qi; Hu, Ying; Chen, Yunyan; Chen, Danqing; Liang, Zhaoxia

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 2, pp. 363-375. DOI: 10.1007/s13300-022-01352-7
8、Beraprost Sodium Delays the Decline of Glomerular Filtration Rate in Patients with Diabetic Nephropathy: A Retrospective Study
Author: Zhou, Jingjing; Jiang, Shimin; Li, Zhongxin; Li, Wenge

Journal: DIABETES THERAPY. 2023; Vol. 14, Issue 3, pp. 497-506. DOI: 10.1007/s13300-022-01361-6